SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu

💊Dapirolizumab (DZP) is a novel CD40L inhibitor 💊Results from phase 3 trial in #SLE 💊Demonstrated improvement in disease activity & GC tapering 💊More pts on DZP achieved BICLA response vs PBO 💊DZP well tolerated AbL16 #ACR24 @RheumNow https://t.co/dtb8QFKvlN

Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling. In the PHOENYCS GO trial, pts on DZP+SOC achieved BICLA response at wk 48 vs. DZP+PBO -observed efficacy in SRI4, SLEDAI2K, LLDAS, BILAG -reduxn in steroid dose -well tolerated @RheumNow #ACR24 abL16 #ACRBest https://t.co/5tj2uwqeUz

Allogenic CD19 CAR-NK cells in SLE, experience w/22 pts 68% LLDAS remission, no relapse As with others, B cell reconstitution w/naive B cells & surprising safety (only 2 cases low-grade CRS) Lots of potential; still figuring out the particulars #ACR24 @RheumNow Abstr#L17 https://t.co/zLtMNrXIlX

LEVI-04 a novel neurotropin3-i showed: -significant analgesia across all measures -improvement in functional measures and PGA for all doses in a Ph2 RCT - well tolerated Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future @RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU

Late breaking abstract L19 Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease. Key findings: - 53.8% achieved complete response (CR) at Week 8; 85% at any time. - Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk

Grom et al. Emapalumab (anti-IFNg) in MAS in Stills. 39 patient pooled analysis. 54% complete response at week 8, 85% at any time. Clinically meaningful glucocorticoid reduction in 72%. @RheumNow #ACR24 Abstr#L19 https://t.co/U72KCfsUh7 https://t.co/jNxsvhseVf

Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf

Late breaking abstract L16 Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 trial. Key findings: - 49.5% of patients achieved BICLA response at Week 48 vs 34.6% on placebo (p=0.0110). - 60.1% achieved SRI-4 response vs 41.1% on placebo… https://t.co/ZawdsLOxmK https://t.co/gpV3KayIW1

PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb